Day: December 10, 2025

Mr. Christian Hadjiminas, Founder and CEO of THEON, Mr. Joachim Sucker, OCCAR-EA Director, Ms. Christina Canitz, Head of Hensoldt Optronics, Mr. Michael Holzmann, Managing Director of Hensoldt Theon NightVisionMr. Christian Hadjiminas, Founder and CEO of THEON, Mr. Joachim Sucker, OCCAR-EA Director, Ms. Christina Canitz, Head of Hensoldt Optronics, Mr. Michael Holzmann, Managing Director of Hensoldt Theon NightVisionFrom the signing of the agreement Representatives from OCCAR, German and Belgian MoD, THEON and HensoldtFrom the signing of the agreement Representatives from OCCAR, German and Belgian MoD, THEON and HensoldtMr. Christian Hadjiminas, Founder and CEO of THEON, Mr. Joachim Sucker, OCCAR-EA Director, Ms. Christina Canitz, Head of Hensoldt Optronics, Mr. Michael Holzmann, Managing Director of Hensoldt Theon NightVision....

One of the first in the industry to enter partnership through multi-million-dollar cloud technology investment TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) — Global diversified professional services and investment management company, Colliers (NASDAQ and TSX: CIGI), today announced its partnership to innovate with Google Cloud. As a pillar of Colliers’ multi-year technology transformation strategy, the migration to Google Cloud will unlock advanced analytics and AI for new product development and integrated systems. This strategic focus on smart technologies will boost efficiency, elevate client service, and strengthen operational consistency to drive future innovation.  “Colliers is leading the way with bold, purposeful investments in technology that transform how we deliver value across the built environment. These investments align...

EXOSENS AND THEON INTERNATIONAL ANNOUNCE THE SIGNING OF A CONTRACT WITH OCCAR FOR 100,000 NIGHT-VISION MIKRON BINOCULARS, EMBEDDING 200,000 EXOSENS TUBES FOR A TOTAL VALUE OF APPROXIMATELY €500 MILLION, THE LARGEST FIRM NIGHT-VISION AGREEMENT TO DATE AND MAJOR STEP FOR EUROPEAN DEFENCE CAPABILITIES PRESS RELEASEMÉRIGNAC, FRANCE – 10 DECEMBER 2025Exosens and Theon International announce the signing of a contract between the THEON/HENSOLDT consortium and OCCAR for 100,000 binocular MIKRON devices, the largest contract ever concluded in the history of night-vision technology, to supply the German Armed Forces. This contract embeds 200,000 Exosens 16mm tubes for a total value of more than €500 million and follows previous agreements to equip the German Armed Forces, for deliveries from 2027 to 2029. This agreement strengthens Exosens’ position...

Villers-lès-Nancy, December 10, 2026, 6:00 p.m. CET – Equasens (ISIN: FR 0012882389 – Ticker: EQS), a leader in digital solutions for healthcare professionals, announces its financial calendar for the 2026 financial year.Events Dates2025 annual revenue February 5, 2026 (after market close)2025 annual results March 30, 2026 (before market opens)2026 Q1 revenue April 29, 2026 (after market close)Annual General Meeting June 25, 20262026 Half-year revenue July 30, 2026 (after market close)2026 Half-year results September 28, 2026 (before market opens)2026 Q3 revenue October 29, 2026 (after market close)About the Equasens Group Founded over 35 years ago, Equasens Group, a leader in digital healthcare solutions, today employs over 1.400 people across Europe.         Equasens Group’s specialised business applications...

Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated cholangiocarcinoma (CCA), positioning this novel combination as a potential new therapeutic approach for difficult-to-treat cancers:No dose limiting toxicity reached to date, enabling recruitment of a third patient cohort GNS561 and MEKi combination demonstrated disease stabilization in all evaluable patients with evidence of tumor shrinkage in a subset of patients, warranting further investigation Recommended Phase 2 doses expected for 1H26Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), December 10, 2025 – GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases,...

EssilorLuxottica joins forces with Fondazione Chips-ITto accelerate the future of smart eyewear Paris, France (10 December 2025) – EssilorLuxottica announces it is joining forces with Fondazione Chips-IT, Italy’s research center specializing in advanced integrated-circuit design, during today’s presentation of the foundation’s 2026-2028 strategic plan. This collaboration aims to further strengthen the Group’s leadership in smart eyewear by advancing application-specific chip development within Chips-IT’s open-hardware environment, unlocking new levels of customization, optimization and performance. By working closely with Chips-IT engineers and select industry partners, EssilorLuxottica will seek to deliver enhanced capabilities and elevate the next generation of wearables. Aligned with its open and collaborative approach, EssilorLuxottica...

   Le 10 décembre 2025Information relative au nombre total de droits de vote et d’actions composant le capital social   Article 223-16 du Règlement Général de l’Autorité des Marchés FinanciersPlace de cotation :        Euronext Paris Compartiment :        Compartiment ACode ISIN :                FR0000054470Site web :                www.ubisoftgroup.com Information mensuelle au 30 novembre 2025(Articles L. 233-8, II, du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers)Date Nombre total d’actions composant le capital social Nombre total de droits de voteTotal brut (1) Total net (2)30/11/2025 134 630 764 148 710 417 148 710 417        Le nombre de droits de vote bruts (ou droits de vote « théoriques »), sert de base de calcul pour les franchissements de seuils. Conformément à l’article...

  Press Release  Paris – December 10, 2025 – EUROAPI today announces that, following the resignation of Rodolfo Savitzky from his position as Independent Director (effective December 31, 2025)1, and upon the recommendation of the Nominations and Compensation Committee, the Board of Directors has decided to co-opt Tristan Imbert as Independent Director, subject to the vote of EUROAPI Shareholders’ meeting on May 27, 2026. Tristan Imbert will be appointed Chair of the Audit Committee, effective January 01, 2026, succeeding Rodolfo Savitzky. A French national, Tristan Imbert began his career in R&D at Sanofi Aventis in 1989. In 2000, he joined the Boston Consulting Group, advising pharmaceutical industry clients in New York and Paris, before moving to Novartis in 2005 as Head of Strategic Planning. At Novartis, he held several...

Press release – Neuilly-sur-Seine, Wednesday, December 10, 2025 – 5.45 pm ARGAN accelerates with the acquisition of three new premium sites leased to FERRERO and PUMA, totalling nearly 100,000 sq.m ARGAN confirms the strengthening of its investment momentum with three new logistics sites scheduled for delivery in the first half of 2026. These buildings are already leased to leading tenants under long-term agreements. ARGAN welcomes two major tenants: FERRERO and PUMA ARGAN has secured two new tenant clients through the acquisition of three development sites that are already fully leased to FERRERO and PUMA. The first building, intended for PUMA—historically established in the Grand Est region—has been developed near Strasbourg (67) in the Vendenheim logistics zone. Early 2026, this 42,000 sq.m site will host the sportswear company’s teams...